As contrast market founders, radiopharmaceuticals show promise

04/30/2013 | DOTMed.com

The decline in the U.S. contrast agents market is likely to last until 2017, according to this article. Companies expected to be affected include GE Healthcare, Mallinckrodt and Lantheus Medical Imaging. However, analyst Ravindra Sharma said the radiopharmaceuticals sector is a promising area, and the CMS decision on Amyvid will be watched closely. Another trend in the field is advancement not just in the chemical composition of contrast agents but in how they are administered, such as in the use of software to allow for integration of injectors, PACS and imaging devices.

View Full Article in:

DOTMed.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY